Alpha Teknova, Inc. (TKNO), is a leading biotechnology firm primarily creating top-tier solutions and products for the life sciences sector. The company, which is publicly traded under the ticker symbol TKNO, is headquartered in Hollister, California, and was established in 1988.
Alpha Teknova's key mission is to facilitate research and advance scientific inquiry by developing and manufacturing high-quality research and diagnostic products. The company's major specialization lies in molecular biology reagents such as buffers, media, and sera for research, cell culture, bioproduction, and diagnostic applications.
Being a significant player in the biotechnology industry, Alpha Teknova has consistently shown commitment in meeting the needs of scientists and researchers worldwide. Over the years, they have built a reputation for unparalleled quality, competitive pricing, superior customer service, and fast delivery times. With a broad portfolio of over 5000 products, the company has always prioritized the needs of its customers, helping them in their quest to bring about scientific breakthroughs.
In addition, Alpha Teknova has constantly championed the need for cutting-edge innovation. They have a dedicated research and development team that consistently stay on the pulse of evolving scientific needs, ensuring that the company’s products are not just reactive, but also proactive and pioneering.
The company also places a significant focus on sustainability and environmental responsibility, maintaining lab practices and manufacturing methods that have the least possible negative impact on the environment.
Alpha Teknova's robust business model and dedication to innovation ensure it remains a trusted partner to research institutions, pharmaceutical companies, and diagnostic labs. Over the years, it has expanded its business operations beyond the United States to serve customers globally. The ability to offer consistently high-quality products and services has made Alpha Teknova a go-to resource in the biotechnology sector across the globe.
In summary, Alpha Teknova, Inc., is an example of a resilient, innovative company, steered by the desire to push the boundaries of research and scientific discovery. Irrespective of the complexities of each project, the company’s commitment to superior quality and customer-centred service delivery makes them a key player in the global biotechnology industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article highlights several biotech stocks that reached 52-week highs on September 23, 2026, due to positive developments. Alpha Teknova Inc. (TKNO) saw growth from new products and increased revenue, while Moderna Inc. (MRNA) achieved highs after positive Phase 3 trial results for its melanoma treatment. AtriCure Inc. (ATRC) recorded strong revenue growth with its FDA-approved Afib treatments, and Illumina Inc. (ILMN) climbed due to significant revenue growth in genomics.
Alpha Teknova (TKNO) shares rose 7.1% due to increased trading volume and continued investor interest following recent business updates, including expanded custom manufacturing capabilities and strong second-quarter results. The company's new Fill-Tek Dispensing System also contributed to positive sentiment. While future earnings are expected to grow, analysts recommend monitoring earnings estimate revisions for sustained strength, as the stock currently holds a Zacks Rank #3 (Hold).
This article from Stock Traders Daily provides an AI-driven analysis of Alpha Teknova Inc. (NASDAQ: TKNO), highlighting divergent sentiment across different time horizons and a breakout signal with no resistance above the current price. It outlines institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide investors.
Teknova has launched the Fill-Tek™ Dispensing System, a proprietary solution for filling custom reagent orders into single-use bags. This system allows manufacturers to specify exact bag sizes and quantities from a single lot, eliminating previous constraints imposed by fixed manifold designs and streamlining the custom order process for novel therapies and diagnostics. It enhances Teknova's modular manufacturing platform by offering flexible, high-quality aseptic dispensing from 250 mL to 200 L, with a single Certificate of Analysis for each lot.
This article provides an analysis of Alpha Teknova Inc. (NASDAQ: TKNO) focusing on volatility zones as tactical triggers for trading. It highlights a neutral sentiment across all horizons, suggesting sideways action, and presents three distinct AI-generated trading strategies for different risk profiles: Position Trading, Momentum Breakout, and Risk Hedging. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
This article analyzes Alpha Teknova Inc. (NASDAQ: TKNO) using AI models, identifying strong near and mid-term sentiment that could extend long-term. It highlights the absence of resistance levels above the current price, suggesting significant upside potential. The analysis also provides specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels, along with multi-timeframe signal analysis for various holding periods.
Alpha Teknova Inc (NASDAQ: TKNO) has been upgraded to a Buy rating by BTIG with an $8 price target, following a strong Q2 performance and improved funding in the life sciences sector. Despite this, GuruFocus's GF Value™ metric suggests TKNO is approximately 52.0% overvalued, with a high Price-to-Sales ratio. The company's GF Score™ of 63 indicates moderate financial health, highlighting strong growth and financial strength but weak profitability and valuation.
BTIG has upgraded Alpha Teknova Inc. (NASDAQ:TKNO) from Neutral to Buy, setting a price target of $8.00, following strong second-quarter 2026 results that exceeded revenue and earnings expectations. The company also raised its 2026 revenue guidance due to improved business fundamentals and a better funding environment in life sciences. Despite a significant stock surge and being considered overvalued, BTIG sees further upside from biotech funding, new product launches like Build-Tek, and expanding commercial investments.